ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma

PHASE3TerminatedINTERVENTIONAL
Enrollment

223

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

July 31, 2008

Study Completion Date

April 30, 2012

Conditions
Diffuse Large Cell Lymphoma
Interventions
DRUG

rituximab

375 mg/m2 on D1

Trial Locations (11)

1011

Centre Pluridisciplinaire d'Oncologie, CHUV, Lausanne

31059

Hématologie CHU Purpan, Toulouse

51092

Centre Hospitalier Robert Debré, Reims

59000

Hématologie CHU de Lille, Lille

69495

Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite

75010

Hôpital Saint Louis, Paris

75743

Hématologie Adultes - Hôpital Necker, Paris

76038

Centre Henri Becquerel, Rouen

94010

Hôpital Henri Mondor, Créteil

Unknown

Groupe d'Etude des Lymphomes de l'adulte, Mont-Godinne

Institut Gustave Roussy, Villejuif

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Lymphoma Study Association

OTHER

NCT00140660 - ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma | Biotech Hunter | Biotech Hunter